Form 4: Neogenomics Executive Melody Harris Reports Stock Option Grant and RSU Vesting
SEC Form 4 Filing
Melody Harris, Chief Operations Officer, President, and Head of Informatics at Neogenomics, reports the grant of stock options and restricted stock units (RSUs), as well as the vesting of previously granted RSUs.
Summary
- On February 21, 2025, Melody Harris, a key executive at Neogenomics, was granted 143,266 stock options with an exercise price of $13.05 and 84,317 restricted stock units (RSUs), both vesting ratably over three years.
- On February 23, 2025, 8,443 restricted stock units vested and were converted into common stock.
- 2,056 shares were disposed of to cover tax obligations related to the vesting of RSUs.
- Following these transactions, Ms. Harris directly owns 109,755 shares of Neogenomics common stock.
- Ms. Harris also holds various stock options and restricted/performance stock units granted in previous years, with different vesting schedules and performance criteria.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Positives
- The grant of stock options and RSUs aligns Ms. Harris' interests with those of the shareholders, incentivizing her to drive company performance.
- The vesting schedules of the equity awards encourage long-term commitment from Ms. Harris.
Risks
- The vesting of RSUs could lead to dilution of existing shareholders' equity.
- The value of the stock options and RSUs is dependent on the future performance of Neogenomics' stock price.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation structure and equity ownership of key executives.
Stakeholder Impact
- Shareholders may be interested in the equity ownership of key executives as it aligns their interests with the company's performance.
- Employees may view the equity grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/01/2023 | Ms. Harris was granted 201,613 stock options, vesting ratably over four years. |
| 05/11/2023 | Ms. Harris was granted 39,683 stock options, 21,204 restricted stock units, and 21,204 performance stock units. |
| 02/23/2024 | Ms. Harris was granted 42,344 stock options and 25,330 performance stock units. |
| 05/02/2024 | Ms. Harris was granted 19,984 stock options, 11,939 performance stock units, and 11,939 restricted stock units. |
| 01/13/2026 | Restricted Stock Unit vesting date. |
| 05/11/2026 | Performance Stock Unit vesting date. |
| 02/23/2027 | Performance Stock Unit vesting date. |
| 05/02/2027 | Performance Stock Unit vesting date. |
| 01/01/2030 | Stock options expire. |
| 05/11/2030 | Stock options expire. |
| 02/23/2034 | Stock options expire. |
| 05/02/2034 | Stock options expire. |
| 02/21/2025 | Ms. Harris was granted stock options and restricted stock units. |
| 02/23/2025 | Restricted stock units vested and shares were disposed of for tax obligations. |
| 02/25/2025 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.